Standout Papers

Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculi... 2003 2026 2010 2018 1.1k
  1. Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis (2010)
    Rachel Jones, Jan Willem Cohen Tervaert et al. New England Journal of Medicine
  2. A Randomized Trial of Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies (2003)
    David Jayne, Niels Rasmussen et al. New England Journal of Medicine
  3. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) (2008)
    Chetan Mukhtyar, Denise Scott Brown et al. Annals of the Rheumatic Diseases
  4. Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis (2009)
    Gerald B. Appel, Gabriel Contreras et al. Journal of the American Society of Nephrology
  5. Randomized Trial of Plasma Exchange or High-Dosage Methylprednisolone as Adjunctive Therapy for Severe Renal Vasculitis (2007)
    David Jayne, Gill Gaskin et al. Journal of the American Society of Nephrology
  6. Long-term patient survival in ANCA-associated vasculitis (2010)
    Oliver Floßmann, Annelies E. Berden et al. Annals of the Rheumatic Diseases
  7. EULAR recommendations for the management of primary small and medium vessel vasculitis (2008)
    Chetan Mukhtyar, Loı̈c Guillevin et al. Annals of the Rheumatic Diseases
  8. Histopathologic Classification of ANCA-Associated Glomerulonephritis (2010)
    Annelies E. Berden, Franco Ferrario et al. Journal of the American Society of Nephrology
  9. Avacopan for the Treatment of ANCA-Associated Vasculitis (2021)
    David Jayne, Peter A. Merkel et al. New England Journal of Medicine
  10. ANCA-associated vasculitis (2020)
    A. Richard Kitching, Hans‐Joachim Anders et al. Nature Reviews Disease Primers
  11. T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection (2015)
    Eoin McKinney, James Lee et al. Nature
  12. EULAR recommendations for the management of large vessel vasculitis (2008)
    Chetan Mukhtyar, Loı̈c Guillevin et al. Annals of the Rheumatic Diseases
  13. Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis (2011)
    Mary Anne Dooley, David Jayne et al. New England Journal of Medicine
  14. Randomized Trial of C5a Receptor Inhibitor Avacopan in ANCA-Associated Vasculitis (2017)
    David Jayne, Annette Bruchfeld et al. Journal of the American Society of Nephrology
  15. Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis (2022)
    David Jayne, Brad H. Rovin et al. Annals of the Rheumatic Diseases
  16. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (2024)
    Michael E. Wechsler, Parameswaran Nair et al. New England Journal of Medicine
  17. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)–Associated Vasculitis (2024)
    Jürgen Floege, David Jayne et al. Kidney International

Immediate Impact

1 by Nobel laureates 16 from Science/Nature 75 standout
Sub-graph 1 of 22

Citing Papers

LAG-3, TIM-3, and TIGIT: Distinct functions in immune regulation
2024 Standout
The immunology of type 1 diabetes
2024 Standout

Works of David Jayne being referenced

T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection
2015 StandoutNature

Author Peers

Author Last Decade Papers Cites
David Jayne 21482 13958 7849 514 31.1k
Loı̈c Guillevin 17788 11414 4066 651 27.8k
Peter A. Merkel 13659 8972 3849 379 20.4k
Charles D. Pusey 10617 4614 3991 317 17.9k
Carlo Salvarani 13707 14253 4573 593 24.0k
Cees G. M. Kallenberg 7828 6430 2340 366 17.5k
Raashid Luqmani 12704 7450 3744 294 15.4k
J. T. Lie 13595 7449 1708 267 20.1k
Ulrich Specks 9785 4806 2813 290 13.4k
É. Hachulla 8070 5864 1761 657 21.6k
John H. Stone 5477 15345 1906 373 20.9k

All Works

Loading papers...

Rankless by CCL
2026